Cargando…

Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential

Type 1 diabetes (T1D) is prompted by defective immunological tolerance, an event in which dendritic cells (DCs) are crucial as immune response orchestrators. In fact, they contribute to maintaining tolerance to self-antigens, but they can also prompt an immunogenic response against them, leading to...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez-Fernandez, Silvia, Murillo, Marta, Villalba, Adrian, Perna-Barrull, David, Cano-Sarabia, Mary, Gomez-Muñoz, Laia, Aguilera, Eva, Maspoch, Daniel, Vazquez, Federico, Bel, Joan, Vives-Pi, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892968/
https://www.ncbi.nlm.nih.gov/pubmed/31849983
http://dx.doi.org/10.3389/fimmu.2019.02811
_version_ 1783476123549564928
author Rodriguez-Fernandez, Silvia
Murillo, Marta
Villalba, Adrian
Perna-Barrull, David
Cano-Sarabia, Mary
Gomez-Muñoz, Laia
Aguilera, Eva
Maspoch, Daniel
Vazquez, Federico
Bel, Joan
Vives-Pi, Marta
author_facet Rodriguez-Fernandez, Silvia
Murillo, Marta
Villalba, Adrian
Perna-Barrull, David
Cano-Sarabia, Mary
Gomez-Muñoz, Laia
Aguilera, Eva
Maspoch, Daniel
Vazquez, Federico
Bel, Joan
Vives-Pi, Marta
author_sort Rodriguez-Fernandez, Silvia
collection PubMed
description Type 1 diabetes (T1D) is prompted by defective immunological tolerance, an event in which dendritic cells (DCs) are crucial as immune response orchestrators. In fact, they contribute to maintaining tolerance to self-antigens, but they can also prompt an immunogenic response against them, leading to autoimmunity. Countless factors can potentially impact on the proper functionality of the DCs, which range from altered subset distribution, impaired phagocytic function to abnormal gene expression. Moreover, in T1D, metabolic dysregulation could impair DC functions as well. Indeed, since T1D clinical course is likely to be more aggressive in children and adolescents and entails severe dysglycemia, the aim of this study was to analyze circulating DCs subpopulations in pediatric T1D at different stages, as well as to characterize their phagocytosis ability and tolerance induction potential. Thus, pediatric patients newly diagnosed with T1D, with established disease and control subjects were recruited. Firstly, DCs subsets from peripheral blood were found quantitatively altered during the first year of disease, but recovered in the second year of progression. Secondly, to study the tolerogenic functionality of DCs, liposomes with phosphatidylserine (PS) were designed to mimic apoptotic beta cells, which are able to induce tolerance, as previously demonstrated by our group in DCs from adult patients with T1D. In this study, monocyte-derived DCs from pediatric patients with T1D and control subjects were assessed in terms of PS-liposomes capture kinetics, and transcriptional and phenotypic changes. DCs from pediatric patients with T1D were found to phagocyte PS-liposomes more slowly and less efficiently than DCs from control subjects, inversely correlating with disease evolution. Nonetheless, the transcription of PS receptors and immunoregulatory genes, cytokine profile, and membrane expression of immunological markers in DCs was consistent with tolerogenic potential after PS-liposomes phagocytosis. In conclusion, T1D progression in childhood entails altered peripheral blood DCs subsets, as well as impaired DCs phagocytosis, although tolerance induction could still function optimally. Therefore, this study provides useful data for patient follow-up and stratification in immunotherapy clinical trials.
format Online
Article
Text
id pubmed-6892968
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-68929682019-12-17 Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential Rodriguez-Fernandez, Silvia Murillo, Marta Villalba, Adrian Perna-Barrull, David Cano-Sarabia, Mary Gomez-Muñoz, Laia Aguilera, Eva Maspoch, Daniel Vazquez, Federico Bel, Joan Vives-Pi, Marta Front Immunol Immunology Type 1 diabetes (T1D) is prompted by defective immunological tolerance, an event in which dendritic cells (DCs) are crucial as immune response orchestrators. In fact, they contribute to maintaining tolerance to self-antigens, but they can also prompt an immunogenic response against them, leading to autoimmunity. Countless factors can potentially impact on the proper functionality of the DCs, which range from altered subset distribution, impaired phagocytic function to abnormal gene expression. Moreover, in T1D, metabolic dysregulation could impair DC functions as well. Indeed, since T1D clinical course is likely to be more aggressive in children and adolescents and entails severe dysglycemia, the aim of this study was to analyze circulating DCs subpopulations in pediatric T1D at different stages, as well as to characterize their phagocytosis ability and tolerance induction potential. Thus, pediatric patients newly diagnosed with T1D, with established disease and control subjects were recruited. Firstly, DCs subsets from peripheral blood were found quantitatively altered during the first year of disease, but recovered in the second year of progression. Secondly, to study the tolerogenic functionality of DCs, liposomes with phosphatidylserine (PS) were designed to mimic apoptotic beta cells, which are able to induce tolerance, as previously demonstrated by our group in DCs from adult patients with T1D. In this study, monocyte-derived DCs from pediatric patients with T1D and control subjects were assessed in terms of PS-liposomes capture kinetics, and transcriptional and phenotypic changes. DCs from pediatric patients with T1D were found to phagocyte PS-liposomes more slowly and less efficiently than DCs from control subjects, inversely correlating with disease evolution. Nonetheless, the transcription of PS receptors and immunoregulatory genes, cytokine profile, and membrane expression of immunological markers in DCs was consistent with tolerogenic potential after PS-liposomes phagocytosis. In conclusion, T1D progression in childhood entails altered peripheral blood DCs subsets, as well as impaired DCs phagocytosis, although tolerance induction could still function optimally. Therefore, this study provides useful data for patient follow-up and stratification in immunotherapy clinical trials. Frontiers Media S.A. 2019-11-28 /pmc/articles/PMC6892968/ /pubmed/31849983 http://dx.doi.org/10.3389/fimmu.2019.02811 Text en Copyright © 2019 Rodriguez-Fernandez, Murillo, Villalba, Perna-Barrull, Cano-Sarabia, Gomez-Muñoz, Aguilera, Maspoch, Vazquez, Bel and Vives-Pi. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Rodriguez-Fernandez, Silvia
Murillo, Marta
Villalba, Adrian
Perna-Barrull, David
Cano-Sarabia, Mary
Gomez-Muñoz, Laia
Aguilera, Eva
Maspoch, Daniel
Vazquez, Federico
Bel, Joan
Vives-Pi, Marta
Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential
title Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential
title_full Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential
title_fullStr Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential
title_full_unstemmed Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential
title_short Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential
title_sort impaired phagocytosis in dendritic cells from pediatric patients with type 1 diabetes does not hamper their tolerogenic potential
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892968/
https://www.ncbi.nlm.nih.gov/pubmed/31849983
http://dx.doi.org/10.3389/fimmu.2019.02811
work_keys_str_mv AT rodriguezfernandezsilvia impairedphagocytosisindendriticcellsfrompediatricpatientswithtype1diabetesdoesnothampertheirtolerogenicpotential
AT murillomarta impairedphagocytosisindendriticcellsfrompediatricpatientswithtype1diabetesdoesnothampertheirtolerogenicpotential
AT villalbaadrian impairedphagocytosisindendriticcellsfrompediatricpatientswithtype1diabetesdoesnothampertheirtolerogenicpotential
AT pernabarrulldavid impairedphagocytosisindendriticcellsfrompediatricpatientswithtype1diabetesdoesnothampertheirtolerogenicpotential
AT canosarabiamary impairedphagocytosisindendriticcellsfrompediatricpatientswithtype1diabetesdoesnothampertheirtolerogenicpotential
AT gomezmunozlaia impairedphagocytosisindendriticcellsfrompediatricpatientswithtype1diabetesdoesnothampertheirtolerogenicpotential
AT aguileraeva impairedphagocytosisindendriticcellsfrompediatricpatientswithtype1diabetesdoesnothampertheirtolerogenicpotential
AT maspochdaniel impairedphagocytosisindendriticcellsfrompediatricpatientswithtype1diabetesdoesnothampertheirtolerogenicpotential
AT vazquezfederico impairedphagocytosisindendriticcellsfrompediatricpatientswithtype1diabetesdoesnothampertheirtolerogenicpotential
AT beljoan impairedphagocytosisindendriticcellsfrompediatricpatientswithtype1diabetesdoesnothampertheirtolerogenicpotential
AT vivespimarta impairedphagocytosisindendriticcellsfrompediatricpatientswithtype1diabetesdoesnothampertheirtolerogenicpotential